Abstract. For the teaching and / or learning about drug actions and for the discovery and development of new drugs, it is important to understand how drugs act on living bodies. So far, there has been no clear description on the general principle of drug action in pharmacology textbooks. We propose two principles to depict the action mechanism of drugs. The first is that most, if not all, drugs act on proteins at the molecular level, that is, enzymes, receptors, ion channels, and transporters. The second is that a drug may cause divergent or convergent responses, resulting in changes of a physiological or pathological function of the human body. The concept of divergence and convergence can be used to explain the complex individuality of drug actions.
Introduction
Drugs have become more and more important in the treatment and prevention of diseases and have also been used as probes in studies of physiological functions. Pharmacology is an interdisciplinary science that requires broad knowledge of basic and clinical medicines. Therefore, it is relatively hard to teach and / or learn pharmacology. Another reason for this difficulty is the fact that often the principle of pharmacology is not clearly described and taught. Usually, the individuality of each drug is emphasized. Here, we should like to address our views on the two general principles of drug action: the targets of most drugs are proteins, and drugs cause changes of physiological functions in divergent and/ or convergent modes. This description may seem to be self-explanatory and to amount to nothing new. To our knowledge, however, these views have not been systematically described in any publications. The first view is described in most textbooks, but only briefly in separate chapters (1 -12) . Although the second view is similar to that concerning the pharmacodynamic action of drugs, the idea of divergence and convergence is more essential and concise than that of pharmacodynamics; in other words, the concept of divergence and convergence can easily explain the complexity and individuality of drug actions.
General principles of drug action
In this article, we would like to propose our ideas for making pharmacology as easily understandable as possible for undergraduate and graduate students, newcomers, and even specialists. Our ideas are based on two principles: one is that drugs act on biomolecules, particularly proteins, and the other is that drugs only change or modulate physiological and pathological functions of the whole body in a manner characterized by divergence and / or convergence. Table 1 summarizes the targets of drugs. Biomolecules in the human body are high molecular weight compounds (e.g., polysaccharides, lipids, nucleic acids, and proteins) and low molecular weight ones (e.g., ions; heavy metals; bioactive substances like autacoids, neurotransmitters, vitamins, and hormones; building constituents of the body like sugars, fatty acids, nucleo-tides, and amino acids; their metabolites and exocrine products; and water). At the molecular level, drugs can act on such endogenous molecules (Table 1) , but most drugs act on the proteins. Of course, we admit that not all medicines (such as acid neutralizers, metal chelators, absorbents, rehydrating agents) act on protein. Therefore, the idea that most drugs act on protein(s) may be an oversimplification, but even the drugs that act on other molecules in the first step evoke their final effects through changes in protein functions. To mention two examples, general anesthetics were previously thought to directly act on membrane lipids and to indirectly influence the functions of membrane proteins such as Na + channels. However, it has recently been proposed that they directly bind to the ligand-gated ion channels of Na + and Cl - (13, 14) . In addition, anti-tumor drugs like dactinomycin and mitomycin act on nucleic acids but eventually inhibit enzymes like RNA and / or DNA polymerases. Figure 1 shows a scheme of our concept concerning drug action. First, most drugs act on proteins at the molecular level (Fig. 1a) . Second, in some cases, an action of a drug on a single protein results in modulations of various physiological functions (divergence) (Fig. 1b) , whereas in other cases, the actions of drugs on multiple targets cause a change in a single physiological function (convergence) (Fig. 1c) . The combination of divergence and convergence may explain most of the drug actions to tissues and / or organs.
Most drugs act on proteins
As described above, the major targets of drugs are Table; examples of such drugs are antibacterial (penicillin, streptomycin), antifungal (amphotericin), and antiviral (acyclovir) drugs, respectively. This review deals with drugs acting directly on the human body. However, the idea described here may be easily applied to chemotherapeutic drugs as well.
b
Recent studies show that general anesthetics act on ligand-gated channels (13) . ACE, angiotensin-converting enzyme. proteins, which may be classified into 4 categories, that is, enzymes, receptors, ion channels, and transporters (Table 2) .
Enzymes as targets of drugs
There are many drugs that act on enzymes, resulting in the activation or inhibition of enzyme reactions, that is, activators and inhibitors, respectively. Typical examples are nitroglycerine and sildenafil as an activator of guanylate cyclase or an inhibitor of phosphodiesterase (PDE), respectively. Both drugs increase the cGMP levels, leading to the relaxation of blood vessels.
Receptors as targets of drugs
We would like to propose in our classification three types of receptors: G-protein-coupled, tyrosine kinasecoupled, and cytoplasmic and / or nuclear receptors, in contrast to the usual four types including ligand-gated ion channels such as nicotinic acetylcholine (nACh), gaminobutyric acid (GABA) A , and N-methyl-D-aspartate (NMDA) receptors, because these latter receptors per se are ion channels. G-protein-coupled receptors for monoamines, peptides, and eicosanoids are the targets of many drugs and about 45% of the currently available drugs belong to this category (15) . Typical examples are salbutamol and haloperidol, whose receptors are b 2 and dopamine receptors, respectively.
In tyrosine kinase-coupled receptors, endogenous agonists such as insulin and cytokines (e.g., interleukins, interferons, colony stimulating factors, erythropoietin, etc.) are used as therapeutic agents. At present, there are few drugs of low molecular weight directed to this type of receptor, but the number of such drugs may increase in the near future with the elucidation of the molecular mechanisms of cellular proliferation and differentiation. In fact, recently, gefitiniv and imatiniv, inhibitors of epidermal growth factor (EGF)-and BCR / ABL-coupled tyrosine kinases, respectively, have been introduced as drugs for non-small cell lung carcinoma and chronic myeloblastic leukemia (16, 17) .
Steroid hormones, thyroxine, and vitamin D bind to the nuclear receptors and corresponding responsive elements in DNA, resulting in the regulation of gene expression.
Ion channels as target(s) of drugs
There are two types of ion channels, ligand-gated (such as nACh receptor or GABA A receptor) and voltage-gated (Na + and Ca 2+ channels), as described below. The ligand-gated channel is opened by amines (ACh and serotonin (5-HT) through nACh receptor and 5-HT 3 receptor, respectively), amino acids (GABA through GABA A receptor), and small molecules (ATP through K ATP ), which are one of the important targets of drugs such as suxamethonium, ondansetron, benzodiazepines, and tolbutamide, respectively. The voltagesensitive Na 
Transporters as targets of drugs
A pump is a transporter that requires ATP as energy to carry ions upstream against a gradient, whereas the other transporters use an ion gradient as an energy source to carry substances across the cell membrane. Typical drugs acting on pumps and transporters are digoxin and thiazides, respectively; they influence the transport of ions such as Na + and Na
Imipramine and fluoxetine are other examples of transporter-inhibiting drugs; they especially interfere with the transport of monoamines and are used as antidepressants. It should be noted that in each translocation step of a drug across the membrane, a drug transporter is involved. Therefore, transporters may become increasingly important as drug targets in the future, especially in terms of drug delivery.
Drugs change physiological and pathological functions in divergent and / or convergent ways
We propose the idea of the divergent and convergent modes of actions of drugs to explain their complex effects on the human body including side actions.
A drug causes divergent effects
Even if a drug simply acts on a protein, it can cause various effects in different organs (divergence) (Fig. 1b) . An example of divergence is aspirin (Fig. 2a) . Aspirin has analgesic, antipyretic, anti-inflammatory, and antiplatelet effects because it inhibits cyclooxygenase (COX), resulting in a decrease in the formation of prostaglandins (PG)s that are involved in pain, fever, inflammation, and platelet aggregation. Furthermore, aspirin has a uricosuric action because it inhibits the organic anion transporter (OAT) that is involved in renal reabsorption of uric acid. The divergence idea of drug action is convenient for explaining the side effects of drugs (see below).
Drugs cause a convergent effect
On the other hand, several drugs with different mechanisms and sites of action may cause the same effect (convergence) (Fig. 1c ). An example of convergence is anti-ulcer drugs with the receptors as targets (Fig. 2b) . Histamine, acetylcholine (ACh), and gastrin stimulate but PGE 2 inhibits the secretion of gastric acid. Therefore, cimetidine, pirenzepine, and proglumide (histamine H 2 , muscarinic M 1 , and gastrin receptor antagonists, respectively) and misoprostol (a prostaglandin E (EP) receptor agonist) are used as anti-ulcer drugs.
Drugs act in convergence and divergence
We propose that most drugs act through a convergence and / or divergence mechanism that combines the two mechanisms described above. The following are two examples. The first example is anti-ulcer drugs (Fig. 2c) . It is well known that peptic ulcers are evoked by the disturbance of a balance between the acid production and the mucosal cytoprotection. In fact, the reduction of H + secretion is induced either by the inhibition of H 2 , M 1 , and gastrin receptors which increase acid secretion or by the enhancement of PGE action that suppresses acid secretion as shown in Fig. 2b . Of these, the H 2 receptor # is most important because H 2 blockers are more effective than the other receptor agents. Another way to reduce acid secretion in the stomach cavity is the inhibition of H + / K + -ATPase (proton pump) with omeprazole as a representative drug. In the cytoprotection system, PG may play major roles, although the precise molecular mechanism is not known. Since nonsteroidal anti-inflammatory drugs (NSAID)s inhibit the production of PGE 2 and PGI 2 which reduce the gastric acid production and have also cytoprotective actions on the gastric mucosa, the long-term administration of NSAIDs for its analgesic effect in patients of rheumatoid arthritis results in the formation of gastric ulcers as a side effect. Thus, this side effect of NSAIDs may be protected by co-administration of PG agonists. There are many other drugs with cytoprotective actions. Eradication of Helicobacter pylori is also effective in the protection against remissions of peptic ulcers. Proton pump inhibitors are used for this purpose, being another example of divergence.
Second, bronchial asthma is characterized by chronic inflammation of the airway tracts, oversecretion of mucus, and hypersensitivity to various stimuli, leading to bronchial constriction, which is the most obvious sign of the disease. Upon stimulation, mast cells release histamine, leukotriene (LT) C 4 , and thromboxane (TX) A 2 , all of which contract the smooth muscle of the bronchus through histamine H 1 , cysteinyl leukotriene (CysLT), and TP receptors, respectively. In this respect, H 1 , LTC 4 , and TXA 2 antagonists, that is, epinastatine, pranlukast, and seratrodast, respectively, inhibit the contraction caused by the activation of these receptors, resulting in relaxation of bronchial smooth muscles (Fig. 2d) . In this scheme, there are various targets of anti-asthma drugs: inhibitions of the "activation" of mast cells [2] and release of chemical mediators [3] , receptor # Recent studies using histamine H2 receptor-gene knockout (H2R-KO) mice showed that histamine and ACh are involved in acid secretion and the action of gastrin is mediated through the H2 receptor because gastrin does not cause acid secretion in H2R-KO mice (18) . Similar results were obtained in studies using L-histidine decarboxylase (a histamine-forming enzyme) gene-knockout mice (19) .
antagonism of the mediators [4] , and direct bronchodilation [5] (Fig. 2d) . However, steroid application is the most effective therapy, but care should be taken to avoid its side effects.
Conclusions
In this review, we propose two ideas on the principle of drug action: 1) the major targets of drugs are proteins and 2) drugs act in convergent and / or divergent ways, resulting only in changes of the physiological functions of the human body or in pathological processes. These general principles of drug action may be of help in the understanding, teaching, and learning of pharmacology. So far, to our knowledge, no such a principle has been proposed as explicitely as in this article. Fig. 2 . Examples of divergent, convergent, and divergent/convergent modes of drug actions. a: Asprin as an example of divergence. Aspirin inhibits COX, resulting in analgesic, anti-pyretic, anti-inflammatory, and antiplatelet actions. Moreover, it inhibits OAT, and thus evokes a uricosuric effect. b: Anti-ulcer drugs with receptors as targets as an example of convergence. Cimetidine, pirenzepine, and proglumide (H2, M1, and gastrin receptor antagonists, respectively) and misoprostol (EP receptor agonist) inhibit the gastric acid secretion and are anti-ulcer drugs. c: Anti-ulcer drugs as an example of divergence and convergence. Drugs acting on the inhibition of gastric acid secretion and the cytoprotection are all anti-ulcer in a convergent way. Furthermore, PGE and PGI receptor agonists and proton pump inhibitors, both of which inhibit the gastric acid production, have divergent effects. Namely, the former drugs have a cytoprotective action and the latter ones are used for eradication of H. pyroli. d: Possible action sites of anti-asthmatic drugs (except glucocorticoids). When an antigen binds to the corresponding IgE bound on the IgE receptor of the mast cell membrane, various chemical mediators such as histamine, LTC4, and TXA2, which act on their respective receptors and cause bronchial smooth muscle constriction, are released. In this series of events, there are many targets of anti-asthma agents: [1] inhibition of IgE production and avoidance of exposure to antigen, [2] inhibition of binding of antigen to IgE (mast cell activation), [3] inhibition of release of chemical mediators, [4] antagonism to receptors as described below, and [5] dilatation of the bronchial smooth muscle by adrenergic b 2 agonists such as salbutamol. Particularly, at step [4] , drugs (epinastine, closed square; pranlukast, closed circle; seratrodast, closed triangle) antagonize the respective histamine, LTC4, and TXA2 receptors of the bronchial smooth muscle, respectively, resulting in bronchial dilatation.
